Immunization

A systematic review reveals declining pediatric pneumococcal complicated pneumonia rates following the introduction of pneumococcal conjugate vaccine 13.

Pharmacists should continue to emphasize the vaccine’s effectiveness in preventing cancer and be prepared to address patient safety concerns.

The vaccine, indicated with a restriction on use for those younger than 65 years and without comorbidities, was proven safe and effective in a series of large clinical trials, and marks the first protein-based vaccine to be approved in the United States.

Explore the latest advancements in RSV vaccination strategies for newborns, focusing on maternal immunization and post-birth protection options.

Like other high-risk groups, children with sickle cell disease have a heightened risk of invasive pneumococcal disease, even if they receive proper pneumococcal conjugate vaccine coverage.

Administration during peak vaccine effectiveness provides maximal protective benefit

FDA and CDC halt Ixchiq chikungunya vaccine for adults 60 years and older due to severe adverse events, including fatalities, urging caution in vaccination practices.

While vaccine research and approvals continue to break new ground, use and faith in them are faltering.

The study found that only 38% of nations have risk-based pneumococcal vaccine policies.

The most substantial reduction was achieved 2 to 3 years after vaccination with a sustained protective effect lasting up to 8 years.

A recent study highlights the promising immune response and safety of the Arexvy vaccine in lung transplant recipients, crucial for preventing RSV infections.

One dose of the vaccine compared with 2 may help increase global HPV vaccine uptake.

In chronic hepatitis B (CHB) mouse models, the ferritin nanoparticle-preS1 (ferritin-NP-preS1) with small interfering RNA (siRNA) showed 100% and sustained serum HBsAg over an approximate 11-month period.

Pharmacists are on the front lines of the outbreak, making them well-positioned to educate and counsel patients with vaccine hesitancy.

Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses how looming tariffs, vaccine misinformation, and rising drug costs are straining public health pharmacy efforts, while also sparking new opportunities for innovation, collaboration, and community-centered care amid uncertainty.

The American Lung Association is raising awareness about updated pneumococcal vaccine guidelines, emphasizing prevention and patient education for at-risk populations.

New research highlights the long-lasting effectiveness of mRNA COVID-19 vaccines, showing sustained B-cell and antibody responses in health care workers over 3 years.

These results suggest that individuals who are immunocompromised with type 2 diabetes (T2D) may need multiple doses of a pneumococcal conjugate vaccine (PCV) to sustain their protection.

The recommendations are not considered to be final until they are published in the Morbidity and Mortality Weekly Report.

Patients who received a pneumococcal 13-valent conjugate vaccination had slightly lower incidence of severe COVID-19 outcomes, but the directions of these associations were mixed.

The findings suggest a positive impact of RSV vaccination on RSV-associated hospital admission, emphasizing the importance of protection in this population.

In a survey among community pharmacists in South Carolina, many pharmacists were unable to correctly identify proper pneumococcal vaccination guideline, raising concerns.

Monetary incentives to receive a COVID-19 vaccine at a public vaccination event may have inadvertently turned away others from receiving a booster, emphasizing the importance of recognizing spillover in trials addressing vaccine hesitancy.

A significant portion of unvaccinated individuals were open to future vaccination.

The poll also showed that social media and general media coverage influenced about 33% of participants to not get vaccinated.

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

The CDC reports 483 total cases across 20 states as of March 28, 2025.

A phase 1/2 clinical trial will provide crucial data on the vaccine's tolerability and pave the way for future development and potential widespread use.

A district leader at CVS Health emphasizes that patients should get tested, be up to date with immunizations, and staying home and reach out to health care professionals when experiencing symptoms.

Jeff A. Goad, PharmD, MPH, discusses the latest RSV vaccination guidelines and recommendations for 2025, highlighting vaccine options, target populations, timing considerations, evolving CDC policies, and the role of pharmacists in immunization efforts.